Log In
BCIQ
Print this Print this
 

APL-2

  Manage Alerts
Collapse Summary General Information
Company Apellis Pharmaceuticals Inc.
DescriptionComplement 3 (C3) inhibitor
Molecular Target Complement 3 (C3)
Mechanism of ActionComplement inhibitor
Therapeutic ModalityPeptide
Latest Stage of DevelopmentPhase II
Standard IndicationAge-related macular degeneration (AMD)
Indication DetailsTreat geographic atrophy (GA) associated with age-related macular degeneration (AMD); Treat intermediate age-related macular degeneration (AMD); Treat wet age-related macular degeneration (AMD)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

11/20/2014

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today